Wanbury Limited has informed the Exchange regarding a press release dated January 28, 2026, titled "Wanbury launches commercial production of key anaesthetic API at Tanuku Facility.".
WANBURY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Wanbury Limited has announced the commencement of commercial production of a key anaesthetic Active Pharmaceutical Ingredient (API) at its Tanuku Facility, effective from a press release dated January 28, 2026. This marks a significant operational milestone, transitioning from development or trial-stage manufacturing to full-scale commercial output. The company is likely positioning itself in the pharmaceutical API market, specifically in the anaesthetics segment, which opens a new revenue stream. Tanuku Facility is now contributing to commercial-scale manufacturing, indicating readiness of infrastructure and regulatory clearances.
This is a positive development for shareholders as it signals potential revenue growth from a new product line. The stock may see short-term positive sentiment as the market evaluates the commercial prospects of the anaesthetic API business.